Somavert
Somavert (pegvisomant) is a growth hormone receptor antagonist. It works by blocking the effects of natural growth hormone (GH) on body tissues, thereby reducing the production of insulin-like growth factor-I (IGF-I), which is responsible for the symptoms and progression of acromegaly.
Dosage by Body Weight
A loading dose of 40 mg is administered subcutaneously under medical supervision. Following this, the standard maintenance dose is 10 mg injected subcutaneously once daily. Dosage adjustments can be made in 5 mg increments or decrements every 4 to 6 weeks based on serum IGF-I concentrations. The maximum maintenance dose should not exceed 30 mg per day.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Somavert is not indicated or approved for pediatric use.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | N/A | Somavert is not indicated or approved for pediatric use. |
| 5-7 kg | Not established | N/A | Safety and efficacy in pediatric patients have not been established. |
| 8-10 kg | Not established | N/A | Safety and efficacy in pediatric patients have not been established. |
| 11-15 kg | Not established | N/A | Safety and efficacy in pediatric patients have not been established. |
| 16-20 kg | Not established | N/A | Safety and efficacy in pediatric patients have not been established. |
Formulation
Purpose
Used to treat acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these treatments are not appropriate.
Generic Name
PegvisomantScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.